The sirtuin-2 inhibitor AK7 is neuroprotective in models of parkinson's disease but not amyotrophic lateral sclerosis and cerebral ischemia

PLoS ONE

Volumn 10, Issue 1, 2015, Pages

  Chen, Xiqun ^a   Wales, Pauline ^b   Quinti, Luisa ^a   Zuo, Fuxing ^a   Moniot, Sébastien ^c   Herisson, Fanny ^a   Rauf, Nazifa Abdul ^a   Wang, Hua ^d   Silverman, Richard B ^d   Ayata, Cenk ^a   Maxwell, Michelle M ^a   Steegborn, Clemens ^c   Schwarzschild, Michael A ^a   Outeiro, Tiago F ^b   Kazantsev, Aleksey G ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^c UNIVERSITY OF BAYREUTH   (Germany)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; AK 7; ALPHA SYNUCLEIN; DOPAMINE; HYDROLASE INHIBITOR; SIRTUIN 2; UNCLASSIFIED DRUG; 3-(1-AZEPANYLSULFONYL)-N-(3-BROMPHENYL)BENZAMIDE; BENZAMIDE DERIVATIVE; MOLECULAR LIBRARY; NEUROPROTECTIVE AGENT; SULFONAMIDE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; CATECHOLAMINE DEPLETION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG PENETRATION; DRUG RESEARCH; DRUG SELECTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; IC50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULAR DOCKING; MOUSE; MOUSE MODEL; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; DISEASE MODEL; HUMAN; METABOLISM; MOLECULAR LIBRARY; PATHOPHYSIOLOGY; PHARMACOLOGY;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; BENZAMIDES; BRAIN ISCHEMIA; CELL LINE; DISEASE MODELS, ANIMAL; HUMANS; MALE; MICE; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; SIRTUIN 2; SMALL MOLECULE LIBRARIES; SULFONAMIDES;

EID: 84921747158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0116919     Document Type: Article

References (40)

1. Donmez G, Outeiro TF (2013) SIRT1 and SIRT2: emerging targets in neurodegeneration. EMBO Mol Med 5(3):344-52. doi: 10.1002/emmm.201302451 PMID: 23417962
2. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E (2003) The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11(2):437-44. PMID: 12620231
3. Taylor DM, Maxwell MM, Luthi-Carter R, Kazantsev AG (2008) Biological and potential therapeutic roles of sirtuin deacetylases. Cell Mol Life Sci 65(24):4000-18. doi: 10.1007/s00018-008-8357-y PMID: 18820996
4. Rauh D, Fischer F, Gertz M, Lakshminarasimhan M, Bergbrede T, et al. (2013) An acetylome peptide microarray reveals specificities and deacetylation substrates for all human sirtuin isoforms. Nat Commun 4:2327-43 doi: 10.1038/ncomms3327 PMID: 23995836
5. Maxwell MM, Tomkinson EM, Nobles J, Wizeman JW, Amore AM, et al. (2011) The Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNS. Hum Mol Genet 20(20):3986-96. doi: 10.1093/hmg/ddr326 PMID: 21791548
6. Beirowski B, Gustin J, Armour SM, Yamamoto H, North AV, et al. (2011) Sir-two-homolog 2 (Sirt2) modulates peripheral myelination through polarity protein Par-3/atypical protein kinase C (aPKC) signaling. Proc Natl Acad Sci USA 108(43):E952-61. doi: 10.1073/pnas.1104969108 PMID: 21949390
7. Ji S, Doucette JR, Nazarali AJ (2011) Sirt2 is a novel in vivo downstream target of Nkx2.2 and enhances oligodendroglial cell differentiation. J Mol Cell Biol 3(6):351-9. doi: 10.1093/jmcb/mjr009 PMID: 21669943
8. Luthi-Carter R, Taylor DM, Pallos J, Lambert E, Amore A, et al. (2010) SIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis. Proc Natl Acad Sci USA 107(17):7927-32. doi: 10.1073/ pnas.1002924107 PMID: 20378838
9. Porcelli S, Salfi R, Politis A, Atti AR, Albani D, et al. (2013) Association between Sirtuin 2 gene rs10410544 polymorphism and depression in Alzheimer's disease in two independent European samples. J Neural Transm 120(12):1709-15. doi: 10.1007/s00702-013-1045-6 PMID: 23712749
10. Wei W, Xu X, Li H, Y Zhang, Han D, et al. (2014) The SIRT2 Polymorphism rs10410544 and Risk of Alzheimer's Disease: A Meta-analysis. Neuromolecular Med 16(2):448-56. doi: 10.1007/s12017-014-8291-0 PMID: 24497179
11. Outeiro TF, Kontopoulos E, Altmann M, Kufareva I, Strathearn KE, et al. (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease. Science 317(5837):516-9. PMID: 17588900
12. Spires-Jones TL, Fox LM, Rozkalne A, Pitstick R, Carlson GA, et al. (2012) Inhibition of Sirtuin 2 with Sulfobenzoic Acid Derivative AK1 is Non-Toxic and Potentially Neuroprotective in a Mouse Model of Frontotemporal Dementia. Front Pharmacol 12; 3:42. doi: 10.3389/fphar.2012.00042 PMID: 22416232
13. Taylor DM, Balabadra U, Xiang Z, Woodman B, Meade S, et al. (2011) A brain-permeable small molecule reduces neuronal cholesterol by inhibiting activity of sirtuin 2 deacetylase. ACS Chem Biol. 6 (6):540-6. doi: 10.1021/cb100376q PMID: 21370928
14. Chopra V, Quinti L, Kim J, Vollor L, Narayanan KL, et al. (2012) The sirtuin 2 inhibitor AK7 is neuroprotective in Huntington's disease mouse models. Cell Rep 2(6):1492-7. doi: 10.1016/j.celrep.2012.11. 001 PMID: 23200855
15. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39(6):889-909. Review. PMID: 12971891
16. Vila M, Przedborski S (2004) Genetic clues to the pathogenesis of Parkinson's disease. Nat Med Suppl: S58-62. Review. PMID: 15272270
17. Körner S, Böselt S, Thau N, Rath KJ, Dengler R, et al. (2013) Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS? Neurodegener Dis 11(3):141-52. doi: 10.1159/000338048 PMID: 22796962
18. Narayan N, Lee IH, Borenstein R, Sun J, Wong R, et al. (2012) The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature 492(7428):199-204. doi: 10.1038/nature11700 PMID: 23201684
19. Newton K, Hildebrand JM, Shen Z, Rodriguez D, Alvarez-Diaz S, et al. (2014) Is SIRT2 required for necroptosis? Nature 506(7489):E4-6. doi: 10.1038/nature13024 PMID: 24572428
20. Nguyen GT, Gertz M, Steegborn C (2013) Crystal structures of sirt3 complexes with 4'-bromo-resveratrol reveal binding sites and inhibition mechanism. Chem Biol 20(11): 1375-1385. doi: 10.1016/j.chembiol.2013.09.019 PMID: 24211137
21. Schutkowski M, Fischer F, Roessler C, Steegborn C (2014) New assays and approaches for discovery and design of Sirtuin modulators. Expert Opin Drug Discov Feb; 9(2):183-99. doi: 10.1517/17460441. 2014.875526 PMID: 24382304
22. Moniot S. Schutkowski M, Steegborn C (2013) Crystal structure analysis of human Sirt2 and its ADP-ribose complex. J Struct Biol 182(2): 136-143. doi: 10.1016/j.jsb.2013.02.012 PMID: 23454361
23. Scholz D, Pöltl D, Genewsky A, Weng M, Waldmann T, et al. (2011) Complete and large-scale generation of post-mitotic neurons from the human LUHMES cell line. J Neurochem 119(5):957-71. doi: 10.1111/j.1471-4159.2011.07255.x PMID: 21434924
24. Schildknecht S, Karreman C, Pöltl D, Efrémova L., Kullmann C, et al. (2013) Generation of geneticallymodified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX 30(4):427-44. PMID: 24173167
25. Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc. 2(1):141-51. PMID: 17401348
26. Gurney ME, Pu H, Chiu AY, Dal Canto MC, Polchow CY, et al. (1994) Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 264(5166):1772-5. PMID: 8209258
27. Scott S, Kranz JE, Cole J, Lincecum JM, Thompson K, et al. (2008) Design, power, and interpretation of studies in the standard murine model of ALS. Amyotroph Lateral Scler. 9(1):4-15. doi: 10.1080/17482960701856300 PMID: 18273714
28. Ludolph AC, Bendotti C, Blaugrund E, Chio A, Greensmith L, et al. (2010) Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph Lateral Scler. 11(1-2):38-45. doi: 10. 3109/17482960903545334 PMID: 20184514
29. Taes I, Timmers M, Hersmus N, Bento-Abreu A, Van Den Bosch L, et al. (2013) Hdac6 deletion delays disease progression in the SOD1G93A mouse model of ALS. Hum. Mol. Genet. 22(9):1783-90. doi: 10.1093/hmg/ddt028 PMID: 23364049
30. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39(6):889-909. Review. PMID: 12971891
31. Maries E, Dass B, Collier TJ, Kordower JH, Steece-Collier K (2003) The role of alpha-synuclein in Parkinson's disease: insights from animal models. Nat Rev. Neurosci. 4(9):727-38. PMID: 12951565
32. Bobrowska A, Donmez G, Weiss A, Guarente L, Bates G (2012) SIRT2 ablation has no effect on tubulin acetylation in brain, cholesterol biosynthesis or the progression of Huntington's disease phenotypes in vivo. PLoS One 7(4):e34805. doi: 10.1371/journal.pone.0034805 PMID: 22511966
33. Outeiro TF, Ferreira J (2009) Current and future therapeutic strategies for Parkinson's disease. Curr Pharm Des 15(34):3968-76. PMID: 19751203
34. Smith JS, Brachmann CB, Celic I, Kenna MA, Muhammad S, et al. (2000) A phylogenetically conserved NAD+-dependent protein deacetylase activity in the Sir2 protein family. Proc Natl Acad Sci USA 97 (12):6658-63. PMID: 10841563
35. Yamagata K, Goto Y, Nishimasu H, Morimoto J, Ishitani R, et al. (2014) Structural basis for potent inhibition of SIRT2 deacetylase by a macrocyclic peptide inducing dynamic structural change. Structure 22(2): 345-352. doi: 10.1016/j.str.2013.12.001 PMID: 24389023
36. Lizée G, Aerts JL, Gonzales MI, Chinnasamy N, Morgan RA, et al. (2003) Real-time quantitative reverse transcriptase-polymerase chain reaction as a method for determining lentiviral vector titers and measuring transgene expression. Hum. Gene Ther. 14(6):497-507. PMID: 12718761
37. Kachroo A, Schwarzschild MA (2012) Adenosine A2A receptor gene disruption protects in an α-synuclein model of Parkinson's disease. Ann. Neurol. 71(2):278-82. doi: 10.1002/ana.22630 PMID: 22367999
38. Chen X, Burdett TC, Desjardins CA, Logan R, Cipriani S, et al. (2013) Disrupted and transgenic urate oxidase alter urate and dopaminergic neurodegeneration. Proc. Natl. Acad. Sci. U S A. 110(1):300-5. doi: 10.1073/pnas.1217296110 PMID: 23248282
39. Wooley CM, Sher RB, Kale A, Frankel WN, Cox GA, et al. (2005) Gait analysis detects early changes in transgenic SOD1(G93A) mice. Muscle Nerve 32(1):43-50. doi: 10.1002/mus.20228 PMID: 15880561
40. Heiman-Patterson TD, Deitch JS, Blankenhorn EP, Erwin KL, Perreault MJ, et al. (2005) Background and gender effects on survival in the TgN(SOD1-G93A)1Gur mouse model of ALS. J. Neurol. Sci. 236 (1-2):1-7. PMID: 16024047